According to BASF, Equateq offers unique technology for fatty acid production comprising proprietary chromatographic separation methods.
BASF (Ludwigshafen, Germany) has acquired omega-3 fatty acids manufacturer Equateq Ltd., expanding the BASF portfolio of omega-3 ingredients for the pharmaceutical and dietary supplement markets. Specifically, BASF says Equateq is a supplier of highly concentrated omega-3 fatty acids and will allow BASF to provide new offerings of highly concentrated omega-3 fatty acids.
According to BASF, Equateq offers unique technology for fatty acid production comprising proprietary chromatographic separation methods that allow for a “customized” approach.
“Equateq’s technologies will enable us to customize fatty acid concentrates with variable ratios of EPA and DHA at concentration levels of up to 99% purity. This is unique in the market,” said Martin Widmann, senior vice president, Pharma Ingredients and Services, which is the division in which Equateq will be integrated. The Pharma Ingredients and Services group is part of BASF’s overall Nutrition and Health division.
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
Krill oil supplementation raises Omega-3 Index of Lupus patients in recent study
July 16th 2024The study was conducted at 20 research centers in the United States by Aker BioMarine and the Lupus Clinical Investigators Network with oversight by Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.